Companies › LigaChem Biosciences
4 active drug programs in 10 registered trials: 6 Phase 1, 4 Phase 2; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Anti-PD-1 monoclonal antibody PD-1 inhibitor | PDCD1 | Phase 1 | Advanced Solid Tumors; Relapsed/Refractory Peripheral T-cell Lymphoma; Renal Cell Carcinoma; Solid Tumors … | Jan 2027 |
| LCB84 TROP2-directed antibody-drug conjugate with monomethyl auristatin E (MMAE) | TROP2 | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| LNCB74 antibody drug conjugate | – | Phase 1 | Ovarian Cancer | Dec 2027 |
| LCB02A anti-CLDN18.2 antibody-drug conjugate with topoisomerase I inhibitor payload | CLDN18 | Phase 1 | Advanced Solid Tumors | Feb 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05182957 | Anti-PD-1 monoclonal antibody | Phase 2 | Relapsed/Refractory Peripheral T-cell Lymphoma | Oncology | Dec 2023 |
| NCT06255223 | Anti-PD-1 monoclonal antibody | Phase 2 | Renal Cell Carcinoma | Oncology | Sep 2026 |
| NCT05522582 | Anti-PD-1 monoclonal antibody | Phase 2 | Solid Tumors | Oncology | Dec 2026 |
| NCT05941507 | LCB84 | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2027 |
| NCT05941507 | Anti-PD-1 monoclonal antibody | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2027 |
| NCT06774963 | LNCB74 | Phase 1 | Ovarian Cancer | Oncology | Dec 2027 |
| NCT06121700 | Anti-PD-1 monoclonal antibody | Phase 2 | Adenocarcinoma | Oncology | Dec 2027 |
| NCT06556199 | Anti-PD-1 monoclonal antibody | Phase 1 | Relapsed/Refractory Primary Central Nervous System Lymphoma | Oncology | Aug 2028 |
| NCT07365592 | Anti-PD-1 monoclonal antibody | Phase 1 | Colorectal Cancer | Oncology | Dec 2029 |
| NCT07460375 | LCB02A | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2030 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.